Welcome to our dedicated page for Cidara Theraptcs news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Theraptcs stock.
Cidara Therapeutics (CDTX) delivers innovative solutions for serious infectious diseases through its Cloudbreak® platform, which engineers targeted immunotherapies and anti-infectives. This page provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements about CDTX's pipeline candidates, antiviral DFC advancements, and partnership agreements. Our curated collection includes press releases on trial results, FDA interactions, and research collaborations – all critical for evaluating the company's progress in addressing unmet medical needs.
Key updates cover three focus areas: clinical trial phases for antifungal/antiviral therapies, technology licensing deals involving the Cloudbreak® platform, and financial developments impacting R&D priorities. Bookmark this resource to monitor how CDTX's dual approach of direct pathogen targeting and immune system engagement evolves across influenza, oncology, and fungal infection programs.
Cidara Therapeutics (Nasdaq: CDTX) announced it will present preclinical data on CD388 at the ASM Microbe 2024 conference, from June 13-17, 2024, in Atlanta, Georgia. CD388 is a novel Drug-Fc Conjugate (DFC) being developed for influenza prevention, using Cidara's proprietary Cloudbreak® platform. The presentation, led by Dr. Voon Ong, will focus on comparing different allometric scaling approaches to project human pharmacokinetics (PK) of CD388. The session, titled 'AAR07 Saturday Antimicrobial Pharmacokinetics and Pharmacodynamics,' will take place on June 15, 2024, from 10:00 AM to 5:00 PM ET at the Exhibit Hall, poster board number AAR-SATURDAY-494.
Cidara Therapeutics (CDTX) announced its Q1 2024 financial results and corporate updates. The company reacquired the global rights to CD388, a universal influenza preventative, from Janssen, and sold its rezafungin program to Mundipharma, aiming to save around $128 million in costs. Cidara raised $240 million through a private placement, led by RA Capital Management. Q1 2024 revenue was $8.5 million, down from $26.1 million in Q1 2023. The company reported a net loss of $10.3 million, compared to a net income of $3.0 million in Q1 2023. R&D expenses decreased to $11.6 million, while SG&A expenses increased to $6.0 million. Cidara conducted a 1-for-20 reverse stock split in April 2024.
Cidara Therapeutics (Nasdaq: CDTX) announced it has regained compliance with Nasdaq's continued listing rules as of May 14, 2024. The company received confirmation from the Nasdaq Listing Qualifications Department. However, the Nasdaq Hearing Panel has imposed a discretionary monitor until May 14, 2025. During this period, any failure to maintain compliance will result in a delist determination letter and a subsequent hearing to address the issue.
FAQ
What is the current stock price of Cidara Theraptcs (CDTX)?
What is the market cap of Cidara Theraptcs (CDTX)?
